Does Aspirin Use Reduce the Risk for Ovarian Cancer?

IF 1.8 4区医学 Q3 ONCOLOGY

Cancer Investigation Pub Date : 2024-08-01 Epub Date: 2024-07-05 DOI:10.1080/07357907.2024.2375573

John P Micha, Mark A Rettenmaier, Randy D Bohart, Bram H Goldstein

引用次数: 0

Abstract

Ovarian cancer is an aggressive malignancy and the leading cause of death among gynecologic cancers. Researchers have evaluated prophylactic medications that potentially avert the manifestation of ovarian cancer, but currently, there are no reliable screening measures for this disease. Nevertheless, the largest study involving aspirin use and ovarian cancer reported a substantive risk reduction from enduring aspirin use. Since there are countervailing data to impugn the potential benefits of aspirin use in staving off ovarian cancer, further research should scrutinize the use of this medication as a prophylactic intervention, especially in women who are at higher risk for developing the disease.

查看原文本刊更多论文

服用阿司匹林会降低罹患卵巢癌的风险吗？

卵巢癌是一种侵袭性恶性肿瘤，也是妇科癌症中的主要死因。研究人员已对可能避免卵巢癌发生的预防性药物进行了评估，但目前还没有针对这种疾病的可靠筛查措施。不过，涉及阿司匹林使用和卵巢癌的最大规模研究报告称，长期服用阿司匹林可大大降低患癌风险。由于有相反的数据对使用阿司匹林预防卵巢癌的潜在益处提出了质疑，因此进一步的研究应该对使用这种药物作为预防性干预措施进行仔细审查，尤其是对那些罹患该疾病风险较高的妇女。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Investigation 医学-肿瘤学

CiteScore

3.80

自引率

4.20%

发文量

审稿时长

8.5 months

期刊介绍： Cancer Investigation is one of the most highly regarded and recognized journals in the field of basic and clinical oncology. It is designed to give physicians a comprehensive resource on the current state of progress in the cancer field as well as a broad background of reliable information necessary for effective decision making. In addition to presenting original papers of fundamental significance, it also publishes reviews, essays, specialized presentations of controversies, considerations of new technologies and their applications to specific laboratory problems, discussions of public issues, miniseries on major topics, new and experimental drugs and therapies, and an innovative letters to the editor section. One of the unique features of the journal is its departmentalized editorial sections reporting on more than 30 subject categories covering the broad spectrum of specialized areas that together comprise the field of oncology. Edited by leading physicians and research scientists, these sections make Cancer Investigation the prime resource for clinicians seeking to make sense of the sometimes-overwhelming amount of information available throughout the field. In addition to its peer-reviewed clinical research, the journal also features translational studies that bridge the gap between the laboratory and the clinic.